Alkermes plc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases
Alkermes plc. (ALKS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases of $500.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases · last filed 2026-02-25
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2025-12-31 was $0.00.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2025-09-30 was $0.00.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2025-06-30 was $0.00.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2025-03-31 was $500.00K.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for fiscal 2025 was $500.00K.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for fiscal 2022 was $500.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $500.00K 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $0.00 derived: sum of 2 quarters · filed 2025-10-28 | $500.00K 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $500.00K 10-Q · filed 2025-07-29 | ||
| 2025-03-31 | $500.00K 10-Q · filed 2025-05-01 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $0.00 derived: sum of 2 quarters · filed 2023-02-16 | $0.00 derived: sum of 3 quarters · filed 2023-02-16 | $500.00K 10-K · filed 2023-02-16 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $500.00K 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $500.00K 10-Q · filed 2022-07-27 | ||
| 2022-03-31 | $500.00K 10-Q · filed 2022-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |